Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AbbVie

How To Attend AbbVie Q1 2022 Earnings Conference Call

AbbVie (NYSE:ABBV) will host a conference call at 09:00 AM ET on April 29, 2022, to discuss Q1 2022 earnings results. How to Attend AbbVie (ABBV) Conference Call Follow this link to access the live webcast.

Benzinga

If You Invested $1000 In AbbVie 5 Years Ago, Here's How Much You Would Have Today

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 7.23% on an annualized basis producing an average annual return of 20.59%. Currently, AbbVie has a market capitalization of $286.37 billion.

Benzinga

7 Warren Buffett Dividend Stocks With The Highest Yields

The stock market rally has run out of steam so far in 2022 as investors grow increasingly concerned about elevated inflation and the potential for aggressive Federal Reserve interest rate hikes. The U.S. economic outlook is uncertain, the war in Ukraine is uncertain and the valuation of growth stocks is…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Will AbbVie And These Two Other Drug Stocks Reinvigorate — Or Incinerate?

A bullish first-quarter report could reinvigorate AbbVie stock, an analyst said Thursday after a C-suite setback this week.

Investors Business Daily

3 Top S&P 500 Stock Market Gainers Today: American Airlines Flies, AbbVie, PayPal Fall On Key Exits

American Airlines led a travel revival Wednesday, while AbbVie and PayPal were stock market losers on key executive exits.

Investors Business Daily

AbbVie Stock Breaks Its Stride As Key Executive Departs For Flagship

AbbVie stock crumbled Wednesday after the company announced President and Vice Chairman Michael Severino will depart at the end of May.

Investors Business Daily

This Investor Is Making Moves In Abbvie, Chipotle And Palo Alto Stock: Here's What He's Buying, What He's Selling

Virtus Investment Partners' Joe Terranova is shaking up his portfolio on Wednesday.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Check Out What Whales Are Doing With ABBV

Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

This Is What Whales Are Betting On AbbVie

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 30 strange trades.

Benzinga

Analyst Ratings For AbbVie

AbbVie (NYSE:ABBV) has observed the following analyst ratings within the last quarter:

Benzinga

Top-Rated AbbVie Stock Hits Record High As It Looks To Expand A Decades-Old Solution

AbbVie stock popped Tuesday after announcing promising test results that could expand use of a treatment for blurry vision.

Investors Business Daily

5 Healthcare Stocks Likely to Withstand a Recession

The healthcare industry has attracted massive investor interest since the onset of the COVID-19 pandemic and could remain in the limelight as COVID cases surge again and necessitate the need for more COVID shots. In addition, the healthcare sector is known to withstand recessions relatively well. So, with several analysts…

StockNews.com

AbbVie Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 39 strange trades.

Benzinga

AbbVie Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stocks That Drive This Fund's Defiance Of Market Downturn

Retirement planning is a challenge for mutual fund shareholders these days. But this portfolio has defied the market's year-to-date swoon.

Benzinga

Looking At AbbVie's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 48 strange trades.

Benzinga

The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

This Is What Whales Are Betting On AbbVie

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 16 strange trades.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

AbbVie, Gedeon Richter Join Forces To Develop Dopamine Receptor Modulators For Neuropsychiatric Diseases

AbbVie Inc (NYSE: ABBV) and Gedeon Richter Plc have

Benzinga

AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar

Alvotech Holdings S.A. has

Benzinga

The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Executives Sell More Than $47M Of 5 Stocks

Although the Bank of Canada raised its key lending rate to 0.5% on Wednesday, there were a few notable insider trades.

Benzinga

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.52% on an annualized basis.

Benzinga

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Looking At AbbVie's Recent Whale Trades

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.